摘要
目的分析吉非替尼靶向治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效,以及对外周循环血清miR-7表达的影响,提出吉非替尼一线治疗晚期NSCLC的安全性和有效性,miR-7表达与NSCLC的关系。方法选择2017-06至2018-06入昌吉州人民医院诊断IIIb^IV期NSCLC患者共80例,均无手术和放疗史,随机将其分为对照组和观察组各40例,对照组采用顺铂+吉西他滨+培美曲塞化疗方案,观察组采用顺铂+吉西他滨+吉非替尼方案,21 d为1个疗程,至少进行4个疗程。比较两组客观缓解率(overall response rate,ORR)、疾病控制率(disease control rate,DCR)和毒副反应,治疗前后血清miR-7、细胞周期蛋白Ki-67和三核苷酸CGG结合蛋白(CGG binding protein 1,CGGBP1)的表达水平。结果观察组ORR和DCR高于对照组,差异有统计学意义(P<0.05),但两组毒副反应率无差异(P>0.05)。两组治疗后血清miR-7水平均较治疗前升高,Ki-67和CGGBP1水平降低,且观察组比对照组改善更明显,差异有统计学意义(P<0.05)。结论吉非替尼作为靶向治疗NSCLC一线化疗方案联合铂类有较好的安全性和有效性,可上调血清miR-7表达,降低细胞周期蛋白Ki-67和CGGBP1水平。
Objective The objective of this study was to analyze the clinical efficacy of gefitinib targeted therapy for non-small cell lung cancer (NSCLC) and influence of microRNA-7 (miR-7) expression in peripheral circulating serum,and to examine the safety and effectiveness of gefitinib as first-line treatment for advanced NSCLC as well as the relationship between miR-7 expression and NSCLC.Methods A total of 80 patients with stage IIIb^IV NSCLC diagnosed in our hospital from June 2017 to June 2018 were selected.They had no history of surgery and radiotherapy.They were randomly divided into control group and observation group,each with 40 patients.The control group received cisplatin + gemcitabine + pemetrexed chemotherapy regimen while the observation group used cisplatin + gemcitabine + gefitinib,21d for one course of treatment and at least for 4 courses.Then overall response rate (ORR),disease control rate (DCR),toxic side effects,serum levels of miR-7,cyclin Ki-67 and CGG binding protein 1 (CGGBP1) before and after treatment were compared.Results In the observation group,the ORR and DCR were both significantly higher than in the control group (P<0.05),while no significant difference of the incidence of toxic side effects was found in the two groups (P>0.05).The level of miR-7 after treatment in the two groups was higher than before treatment,and the levels of Ki-67 and CGGBP1 were reduced.The observation group had a more significant improvement than the control group,and the difference was statistically significant (P<0.05).Conclusions Gefitinib as a first-line chemotherapy regimen for targeted NSCLC combined with platinum has good safety and effectiveness,can increase the expression of serum miR-7,and reduce the levels of cyclin Ki-67 and CGBPP1.
作者
白冰
李茂辉
吉勇
BAI Bing;LI Maohui;and JI Yong(Department of Oncology,Changji People's Hospital,Changji 831100,China)
出处
《中华灾害救援医学》
2020年第1期1-4,共4页
Chinese Journal of Disaster Medicine
